PHARMACEUTICAL REIMBURSEMENT OF INNOVATIVE MEDICINAL PRODUCTS IN BELGIUM

Author(s)

Van Wilder P, Bormans V
SMART&BI, Zaventem, Belgium

OBJECTIVES: The aim of this study was to investigate the reimbursement submissions of innovative medicines and analyze the consistency between the advice of the Commission for Reimbursement of Medicines (CRM) and the decision of the competent Minister. METHODS: Data for submissions in the period 2010-2014 were extracted from the MORSE -report from the National Institute for Health and Disability Insurance (NIHDI)

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHP160

Topic

Health Policy & Regulatory

Topic Subcategory

Reimbursement & Access Policy

Disease

Multiple Diseases, Oncology, Rare and Orphan Diseases

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×